Inhibiting survivin expression enhances TRAIL-induced tumoricidal activity in human hepatocellular carcinoma via cell

Song-Qing He1, Hasibur Rehman, Ming-Guang Gong

  • 1Hepatic Surgery Center, Affiliated with Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Cancer Biology & Therapy
|August 19, 2007
PubMed

Insights

Survivin overexpression in hepatocellular carcinoma (HCC) cells promotes resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell death. Inhibiting survivin sensitizes HCC cells to TRAIL, offering a potential therapeutic strategy for liver cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Death Research

Background:

  • Hepatocellular carcinoma (HCC) cells often resist apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
  • Survivin overexpression has been previously linked to reduced sensitivity in HCC cells towards TRAIL-induced apoptosis.
  • Understanding the mechanisms of TRAIL resistance and identifying strategies to overcome it are crucial for HCC treatment.

Purpose of the Study:

  • To investigate how survivin expression contributes to tumor cell evasion of TRAIL-mediated apoptosis.
  • To explore methods for reversing TRAIL resistance in HCC cells by manipulating survivin levels.
  • To evaluate the combined therapeutic potential of TRAIL and survivin inhibition in vivo.

Main Methods:

  • Cultured seven human HCC cell lines treated with TRAIL protein and survivin antisense oligodeoxynucleotides (ODNs).
  • Cell cycle synchronization of HepG(2) and SMMC7721 cells using mimosine, thymidine, or nocodazole to assess TRAIL sensitivity.
  • In vivo evaluation of TRAIL plasmid and survivin antisense ODNs efficacy in a nude mouse hepatoma model.

Main Results:

  • Survivin mRNA levels negatively correlated with TRAIL-induced apoptosis across different HCC cell lines.
  • HepG(2) and SMMC7721 cells in G(1)/S phase were more sensitive to TRAIL than those in G(2) phase.
  • Survivin antisense ODNs induced S phase arrest and significantly enhanced TRAIL-induced apoptosis; combined treatment suppressed tumor xenograft growth.

Conclusions:

  • Survivin plays a role in HCC cell resistance to TRAIL-induced apoptosis, partly via cell cycle regulation.
  • Modulating survivin expression can sensitize tumor cells to TRAIL-mediated apoptosis.
  • Combined administration of TRAIL and survivin inhibition shows promise for suppressing HCC tumor growth.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...